Drug Trial Radar · NCT05875961
Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
600
Actual
Start
Jun 15, 2023
Primary completion
Nov 15, 2024
Study completion Nov 15, 2024
Sponsor
- Lead sponsor
- SeqirusIndustry
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- May 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1, randomized, observer-blind, dose-ranging clinical study is evaluating 6 different formulations of MF59-adjuvanted and non-adjuvanted H2N3 influenza vaccine. Approximately 600 healthy adult subjects are to be randomized into 1 of 6 possible treatment groups with 100 subjects per group, stratified by age group (born after or before 1968). Each subject will receive an influenza vaccine injection on Day 1 and Day 22. Subjects will be followed up for approximately 12 months after the second vaccine injection. The primary immunogenicity analysis is based on the Day 1, Day 8, Day 22, Day 29, and Day 43 serology data. The primary safety analysis is based on solicited local and systemic adverse events (AEs) reported within 10 days after each vaccination, unsolicited AEs reported within 3 weeks after each vaccination, and serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal from the study, and AEs of special interest (AESIs) reported throughout the study.
Conditions
- Influenza, Human
- Infections
- Respiratory Tract Infections
- Virus Diseases
- Infection Viral
Interventions
Low dose A/H2N3c + standard dose MF59Biological
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
Intermediate dose A/H2N3c + standard dose MF59Biological
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
High dose A/H2N3c + standard dose MF59Biological
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
High dose A/H2N3c non-adjuvantedBiological
Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine
Lowest dose A/H2N3c + high dose MF59Biological
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
Low dose A/H2N3c + high dose MF59Biological
Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric mean titer (GMT) of hemagglutination inhibition (HI) antibodies against homologous H2N3 strain - Day 1Time frame: Day 1
- GMT of HI antibodies against homologous H2N3 strain - Day 8Time frame: Day 8
- GMT of HI antibodies against homologous H2N3 strain Day 22Time frame: Day 22
- GMT of HI antibodies against homologous H2N3 strain - Day 29Time frame: Day 29
- GMT of HI antibodies against homologous H2N3 strain - Day 43Time frame: Day 43
- GMT of microneutralization (MN) antibodies against homologous H2N3 strain - Day 1Time frame: Day 1
- GMT of MN antibodies against homologous H2N3 strain - Day 8Time frame: Day 8
- GMT of MN antibodies against homologous H2N3 strain - Day 22Time frame: Day 22
- GMT of MN antibodies against homologous H2N3 strain - Day 29Time frame: Day 29
- GMT of MN antibodies against homologous H2N3 strain - Day 43Time frame: Day 43
- Geometric mean fold increase (GMFI) of HI antibodies against homologous H2N3 strain - Day 8Time frame: Day 8
- GMFI of HI antibodies against homologous H2N3 strain - Day 22Time frame: Day 22
- GMFI of HI antibodies against homologous H2N3 strain - Day 29Time frame: Day 29
- GMFI of HI antibodies against homologous H2N3 strain - Day 43Time frame: Day 43
- GMFI of MN antibodies against homologous H2N3 strain - Day 8Time frame: Day 8
- GMFI of MN antibodies against homologous H2N3 strain - Day 22Time frame: Day 22
- GMFI of MN antibodies against homologous H2N3 strain - Day 29Time frame: Day 29
- GMFI of MN antibodies against homologous H2N3 strain - Day 43Time frame: Day 43
- Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 1Time frame: Day 1
- Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 8Time frame: Day 8
- Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 22Time frame: Day 22
- Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 29Time frame: Day 29
- Percentages of subjects with HI titers ≥1:40 against homologous H2N3 strain - Day 43Time frame: Day 43
- Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 1Time frame: Day 1
- Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 8Time frame: Day 8
- Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 22Time frame: Day 22
- Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 29Time frame: Day 29
- Percentages of subjects with MN titers ≥1:40 against homologous H2N3 strain - Day 43Time frame: Day 43
- Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 8Time frame: Day 8
- Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 22Time frame: Day 22
- Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 29Time frame: Day 29
- Percentages of subjects with seroconversion by HI against homologous H2N3 strain - Day 43Time frame: Day 43
- Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 8Time frame: Day 8
- Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 22Time frame: Day 22
- Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 29Time frame: Day 29
- Percentages of subjects with seroconversion by MN against homologous H2N3 strain - Day 43Time frame: Day 43
- Number and percentages of subjects reporting solicited local and systemic adverse events (AEs) - Day 1 through Day 10Time frame: Day 1 through Day 10
- Number and percentages of subjects reporting solicited local and systemic AEs - Day 22 through Day 31Time frame: Day 22 through Day 31
- Number and percentage of subjects reporting any unsolicited AEsTime frame: Day 1 through Day 43
- Number and percentage of subjects reporting serious AEs (SAEs), AEs leading to withdrawal, AEs of special interest (AESI) and medically attended AEs (MAAEs)Time frame: Day 1 through Day 387
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Meridian Clinical Research
Rockville, Maryland
Meridian Clinical Research
Lincoln, Nebraska
Meridian Clinical Research
Omaha, Nebraska
West Visayas State University Medical Center
Iloilo City, Philippines
Manila Doctors Hospital
Manila, Philippines
Quirino Memorial Medical Center
Quezon City, Philippines
Silang Specialists Medical Center
Silang, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.